18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Spectrophotometric Methods for the Determination of Linagliptin in Binary Mixture with Metformin Hydrochloride and Simultaneous Determination of Linagliptin and Metformin Hydrochloride using High Performance Liquid Chromatography

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Simple, accurate and precise Zero order, first derivative spectrophotometric and chromatographic methods have been developed and validated for the determination of linagliptin (LNG) and metformin HCl (MET). The zero order and first derivative spectrophotometric methods were used for the determination of LNG in the range of 5-30 μg mL −1 by measuring the absorbance at 299 nm and 311 respectively. Besides, a reversed-phase liquid chromatographic (RP-LC) method is described for the simultaneous determination of LNG and MET. Chromatographic separation was achieved on a Symmetry ® Waters C18 column (150 mm × 4.6 mm, 5 μm). Isocratic elution based on potassium dihydrogen phosphate buffer pH (4.6) - methanol (30:70, v/v) at a flow rate of 1 mLmin −1 with UV detection at 260 nm was performed. Linearity, accuracy and precision were found to be acceptable over the concentration ranges of 0.125-4 μg mL −1 and 20-800 μg mL −1 for LNG and MET, respectively. The results were statistically compared using one-way analysis of variance (ANOVA). The optimized methods were validated and proved to be specific, robust, precise and accurate for the quality control of the drugs in their pharmaceutical preparation.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

          DPP-4 (dipeptidyl peptidase-4) degrades the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide), decreasing their stimulatory effects on beta-cell insulin secretion. In patients with Type 2 diabetes, meal-related GLP-1 secretion is reduced. DPP-4 inhibitors (alogliptin, saxagliptin, sitagliptin and vildagliptin) correct the GLP-1 deficiency by blocking this degradation, prolonging the incretin effect and enhancing glucose homoeostasis. DPP-4 is a member of a family of ubiquitous atypical serine proteases with many physiological functions beyond incretin degradation, including effects on the endocrine and immune systems. The role of DPP-4 on the immune system relates to its extra-enzymatic activities. The intracytosolic enzymes DPP-8 and DPP-9 are recently discovered DPP-4 family members. Although specific functions of DPP-8 and DPP-9 are unclear, a potential for adverse effects associated with DPP-8 and DPP-9 inhibition by non-selective DPP inhibitors has been posed based on a single adverse preclinical study. However, the preponderance of data suggests that such DPP-8 and DPP-9 enzyme inhibition is probably without clinical consequence. This review examines the structure and function of the DPP-4 family, associated DPP-4 inhibitor selectivity and the implications of DPP-4 inhibition in the treatment of Type 2 diabetes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.

            The aim of the present study was to evaluate the effects of monotherapies and combinations of drugs on insulin sensitivity, adipose tissue morphology, and pancreatic and hepatic remodelling in C57BL/6 mice fed on a very HF (high-fat) diet. Male C57BL/6 mice were fed on an HF (60% lipids) diet or SC (standard chow; 10% lipids) diet for 10 weeks, after which time the following drug treatments began: HF-T (HF diet treated with telmisartan; 5.2 mg x kg-1 of body weight x day-1), HF-S (HF diet treated with sitagliptin; 1.08 g x kg-1 of body weight.day-1), HF-M (HF diet treated with metformin; 310.0 mg x kg-1 of body weight x day-1), HF-TM (HF diet treated with telmisartan+metformin), HF-TS (HF diet treated with telmisartan+sitagliptin) and HF-SM (HF diet treated with sitagliptin+metformin). Treated groups also had free access to the HF diet, and treatments lasted for 6 weeks. Morphometry, stereological tools, immunostaining, ELISA, Western blot analysis and electron microscopy were used. The HF diet yielded an overweight phenotype, an increase in oral glucose intolerance, hyperinsulinaemia, hypertrophied islets and adipocytes, stage 2 steatosis (>33%), and reduced liver PPAR-alpha (peroxisome-proliferator-activated receptor-alpha) and GLUT-2 (glucose transporter-2) levels, concomitant with enhanced SREBP-1 (sterol-regulatory-element-binding protein-1) expression (P<0.0001). Conversely, all drug treatments resulted in significant weight loss, a reversal of insulin resistance, islet and adipocyte hypertrophy, and alleviated hepatic steatosis. Only the HF-T and HF-TS groups had body weights similar to the SC group at the end of the experiment, and the latter treatment reversed hepatic steatosis. Increased PPAR-alpha immunostaining in parallel with higher GLUT-2 and reduced SREBP-1 expression may explain the favourable hepatic outcomes. Restoration of adipocyte size was consistent with higher adiponectin levels and lower TNF-alpha (tumour necrosis factor-alpha) levels (P<0.0001) in the drug-treated groups. In conclusion, all of the drug treatments were effective in controlling the metabolic syndrome. The best results were achieved using telmisartan and sitagliptin as monotherapies or as a dual treatment, combining partial PPAR-gamma agonism and PPAR-alpha activation in the liver with extended incretin action.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              United State Pharmacopoeia

              (2005)
                Bookmark

                Author and article information

                Journal
                Int J Biomed Sci
                Int J Biomed Sci
                IJBS
                International Journal of Biomedical Science : IJBS
                Master Publishing Group
                1550-9702
                1555-2810
                March 2013
                : 9
                : 1
                : 41-47
                Affiliations
                [1 ] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt
                [2 ] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, British University in Egypt, El-Sherouk city, Cairo 11837, Egypt
                Author notes
                Corresponding author: Bassam M. Ayoub, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, British University in Egypt, El-Sherouk city, Cairo 11837, Egypt. Tel: +20125104337; Fax: +20224148452; E-mail: drbassamchemistry@ 123456hotmail.com , bassam.ayoub@ 123456bue.edu.eg .
                Article
                IJBS-9-41
                3644414
                23675288
                3a5793d2-fefb-4f51-b729-e2657a3627a6
                © Ramzia I. El-Bagary et al. Licensee Master Publishing Group

                This is an open-access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.5/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 22 December 2012
                : 18 January 2013
                Categories
                Original Article

                linagliptin,metformin hydrochloride,reversed-phase liquid chromatography,spectrophotometry,pharmaceutical preparation

                Comments

                Comment on this article